Lin Zejian, Gu Haifeng, Liu Guochen, Liu Lili, Liu Zhimin, Li Junyun, Zhang Xinke, Tu Hua
Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Yuexiu District, Guangzhou 510060, Guangdong, China.
Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Yuexiu District, Guangzhou 510060, Guangdong, China.
J Surg Case Rep. 2025 Aug 30;2025(8):rjaf671. doi: 10.1093/jscr/rjaf671. eCollection 2025 Aug.
This retrospective study analyzed 27 vulvar sarcoma patients treated at one institution (2005-2024). Mitotic count significantly predicted outcomes: patients with ≥20 mitoses/high power field (HPF) (N = 8) showed drastically worse recurrence-free survival (recurrence-free survival; hazard ratio [HR] = 15.48, 95% confidence interval [CI] = 2.67-89.70, < 0.01) and overall survival (HR = 11.97, 95% CI = 1.40-102.22, = 0.02) versus those with 0-9/HPF (N = 12). Despite adjuvant therapy, the ≥20/HPF group experienced high local and distant recurrence rates (both 62.5%). Mitotic count is a robust prognostic indicator, with ≥20 mitoses/HPF indicating poor survival outcomes even after comprehensive treatment.
这项回顾性研究分析了在一家机构接受治疗的27例外阴肉瘤患者（2005年至2024年）。有丝分裂计数显著预测了预后：每高倍视野（HPF）有丝分裂数≥20个的患者（N = 8）与每HPF有丝分裂数为0 - 9个的患者（N = 12）相比，无复发生存率（无复发生存率；风险比[HR] = 15.48，95%置信区间[CI] = 2.67 - 89.70，P < 0.01）和总生存率（HR = 11.97，95% CI = 1.40 - 102.22，P = 0.02）明显更差。尽管接受了辅助治疗，每HPF有丝分裂数≥20个的组局部和远处复发率均较高（均为62.5%）。有丝分裂计数是一个可靠的预后指标，每HPF有丝分裂数≥20个表明即使经过综合治疗，生存结果也较差。
